Skip to main content
. Author manuscript; available in PMC: 2021 Aug 5.
Published in final edited form as: J Am Coll Cardiol. 2020 Nov 2;76(21):2527–2564. doi: 10.1016/j.jacc.2020.07.023

TABLE 6.

Revised Heart Failure Measures

Measure No. Measure Title Description of Revision Rationale for Revision
5 Patient self-care education Moved from Performance Measure to Quality Measure Concern regarding the accuracy of self-care education documentation; limited evidence of improved outcomes with better documentation.
7 ACE inhibitor or ARB therapy for LVSD Added ARNI 2017 ACC/AHA/HFSA heart failure guideline update (4) made this revision to the recommendation.
9 Postdischarge appointment Moved from Performance Measure to Quality Measure and included a time limit of 7 d 2013 ACCF/AHA heart failure clinical practice guideline (7) lists postdischarge appointment from 7–14 d as a Class 2a recommendation.

ACC indicates American College of Cardiology; ACE, angiotensin–converting enzyme; AHA, American Heart Association; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; HF, heart failure; and LVSD, left ventricular systolic dysfunction.